Albert Bourla, Pfizer CEO (Laurent Gillieron/Keystone via AP Images)

Fol­low­ing FDA, CHMP gives thumbs-up on Pfiz­er, BioN­Tech Omi­cron boost­er

One day af­ter the FDA cleared Pfiz­er’s bi­va­lent boost­er to go af­ter Omi­cron, the phar­ma gi­ant and its part­ners at BioN­Tech are now one step clos­er to an EU au­tho­riza­tion.

Pfiz­er and BioN­Tech joint­ly an­nounced Thurs­day that the EMA’s CHMP com­mit­tee rec­om­mend­ed con­di­tion­al mar­ket­ing au­tho­riza­tion for the pair’s Comir­naty bi­va­lent boost­er for Omi­cron to the Eu­ro­pean Com­mis­sion. The bi­va­lent boost­er, which would be ap­proved in peo­ple ages 12 and up, tar­gets both the wild-type SARS-CoV-2 virus and the Omi­cron sub­vari­ant BA.1.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.